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Abstract
Systemic lupus erythematosus (SLE) is a complex trait characterised by the production of a range of auto-antibodies and a
diverse set of clinical phenotypes. Currently, ,8% of the genetic contribution to SLE in Europeans is known, following
publication of several moderate-sized genome-wide (GW) association studies, which identified loci with a strong effect
(OR.1.3). In order to identify additional genes contributing to SLE susceptibility, we conducted a replication study in a UK
dataset (870 cases, 5,551 controls) of 23 variants that showed moderate-risk for lupus in previous studies. Association
analysis in the UK dataset and subsequent meta-analysis with the published data identified five SLE susceptibility genes
reaching genome-wide levels of significance (Pcomb,5610
28): NCF2 (Pcomb=2.87610
211), IKZF1 (Pcomb=2.33610
29), IRF8
(Pcomb=1.24610
28), IFIH1 (Pcomb=1.63610
28), and TYK2 (Pcomb=3.88610
28). Each of the five new loci identified here can
be mapped into interferon signalling pathways, which are known to play a key role in the pathogenesis of SLE. These results
increase the number of established susceptibility genes for lupus to ,30 and validate the importance of using large
datasets to confirm associations of loci which moderately increase the risk for disease.
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Introduction
Systemic lupus erythematosus (SLE) is a relapsing-remitting
complex trait which most commonly affects women of child-
bearing age, with a ratio of 9:1 in female to males. The disease
prevalence varies with ethnicity, being more prevalent in non-
European populations (approximately 1:500 in populations with
African ancestry and 1:2500 in Northern Europeans) [1]. The
condition is characterised by the production of a diverse range of
auto-antibodies against serological, intra-cellular, nucleic acid
and cell surface antigens [2]. The wide-ranging clinical
phenotypes include skin rash, neuropsychiatric and musculoske-
tal symptoms and lupus nephritis, which may be partially
mediated by the extensive deposition of immune complexes.
Today, thanks to improved treatments, the 10-year survival rate
after diagnosis has increased to 90%, with lower survival rates
being related to disease severity or complications from treatment
[3]. Increased understanding of the underlying genetic basis for
lupus is of key importance in improving the prognosis for lupus
patients.
Until recently, the genetic basis of lupus remained largely
undetermined, with only about ,8% of the genetic contribution
known [4]. However, within the last three years, tremendous
progress has been made in defining novel loci, through three
moderate-sized genome-wide association studies in European
American cohorts and a replication study in a US-Swedish cohort
[5–7]. The loci previously identified for SLE include genes
involved in the innate immune response (eg. IRF5), T and B cell
signalling (eg. STAT4, TNFSF4 and BLK), autophagy/apoptosis
(eg. ATG5), ubiquitinylation (UBE2L3, TNAIP3, TNIP1) and
phagocytosis (ITGAM, FCGR3A and FCGR3B). All of these
pathways are of potential importance in lupus pathogenesis [8–
10].
To date, a total of 1729 independent SLE cases have been
subjected to genome-wide association genotyping using three
genotyping platforms: Illumina 317 K BeadChip [5], Illumina
550 K BeadChip [6] and Affymetrix 500 K array [7]. There is
currently no published meta-analysis of these datasets.
The aim of the current work was to perform a replication study
using our UK SLE cohort on loci that showed some evidence for
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confirmed susceptibility genes for lupus.
Results
To identify additional susceptibility loci for SLE, we first
identified the independent genetic variants that showed moderate
risk (5610
23,P.5610
28) in a combined US-Swedish dataset
comprising 3273 SLE cases and 12188 controls [4]. We then
genotyped 27 independent SNPs in a replication cohort of 905 UK
SLE cases and 5551 UK control samples (Table 1), that included
both British 1958 Birth Cohort samples and additional controls
from the WTCCC2 project.
For the 27 genotyped SNPs, 10 variants which had not been
genotyped by the WTCCC2 project, were imputed using
IMPUTE2 [11]. This imputation was performed using CEPH
HapMap samples as the phased reference sequence and the
boundary of the surrounding haplotype blocks used to demarcate
the imputation interval. The subsequent association analysis
excluded two of these ten imputed SNPs because they had less
than 95% certainty for the imputation (Table S2). In the US/SWE
dataset, imputation of selected SNPs not genotyped previously [4]
was performed using IMPUTE1 for HapMap. Phase II CEU
sample haplotypes were used as reference with subsequent
association analysis performed using SNPTEST and a genomic
control factor (lambda-GC) values of: 1.05 (US dataset) and 1.10
(SWE dataset) after correction for population stratification.
In the UK replication sample by performing allelic association
analysis using PLINK for the 23 SNPs passing QC (Tables S2
and S3), we demonstrated moderate association (P#0.05) for
twelve variants - with a lambda-GC of 1.01 following ancestry
correction (see Table 2 and Table 3). Under the null hypothesis,
only 1 of the 23 loci would be expected to have P#0.05. The
observed enrichment of associated SLE genes in the UK dataset
suggested that many of these loci were likely to be true-positive
associations.
We confirmed the similarity of odds-ratios (Het P value)
and direction of the effect between the UK and US-SWE
datasets (Table S4) and then performed a meta-analysis using
Fisher’s combined P-value (see Materials and Methods). This
meta-analysis revealed five novel associated loci with P,5610
28
(Table 2): NCF2 (neutrophil cytosolic factor 2) (rs10911363,
Pcomb=2.87610
211,O R comb=1.19); IKZF1 (Ikaros family zinc-
finger 1) (rs2366293, Pcomb=2.33610
29,O R comb=1.24); IRF8
(interferon regulatory factor 8) (rs2280381, Pcomb=1.24610
28,
ORcomb=1.16); IFIH1 (interferon-induced helicase C domain-
containing protein 1) (rs1990760, Pcomb=1.63610
28,O R comb
=1.15) and TYK2 (tyrosine kinase 2) (rs280519, Pcomb
=3.88610
28,O R comb=1.17)(Table 1). The strength of these
associations was similar to those found from a weighted meta-
analysis, using the METAL programme (Table S4). A case-only
analysis using PLINK in the combined UK/US/SWE dataset
revealed no non-additive interactions between the five newly
associated variants (P.0.05). These new SLE loci are discussed in
more detail below and with additional information in Text S1.
Three of the SNPs tested were for loci that had shown genome-
wide levels of significance in other SLE GWAS studies (Table S5).
In the UK cohort we found further support for the association at
JAZF1 (rs849142 PUK=0.0243, ORUK=1.13) and identified a
third associated variant in the first intron of TNIP1 (rs6889239
PUK=9.06610
26,O R UK=1.30), which is in strong LD
(r
2=0.895) with both the previous report in Europeans [4] and
in perfect LD with a third SNP (rs10036748), first reported in a
Chinese GWAS [12]. All three variants in TNIP1 are located
Table 1. SLE Case-Control Study Cohorts used in the study.
Study Origin of Samples SLE cases Control samples
UK
a US
c SWE
d UK (B58BCC)
a UK (WTCCC2)
b US
c SWE
d
UK UK 870 68 5483
US GWAS Gateva et al (2009) [4] 1310 7859
US replication Gateva et al (2009) [4] 1129 2991
SWE replication Gateva et al (2009) [4] 834 1338
Total 870 2439 834 5551 10850 1338
Each of the seven groups of samples included in this manuscript was independent from each other. In the UK population, direct genotyping was carried out on 905 UK
cases
a and samples from the British Birth Control Cohort
a (B58BCC). A total of 905 UK SLE cases were typed and for the analysis, 35 cases were removed following QC.
Genotypes from the WTCCC2
b were used as out-of-study controls. The published data used for the meta-analysis described in this current manuscript was derived from
US and Swedish samples. The US cohort
c consisted of samples included in a GWAS and additional non-GWAS’d samples used just for the replication study, as described
by Gateva et al. (2009) [4]. Full details of the Swedish (SWE)
b replication samples are also described in Gateva et al. (2009) [4].
doi:10.1371/journal.pgen.1002341.t001
Author Summary
Genome-wide association studies have revolutionised our
ability to identify common susceptibility alleles for
systemic lupus erythematosus (SLE). In complex diseases
such as SLE, where many different genes make a modest
contribution to disease susceptibility, it is necessary to
perform large-scale association studies to combine results
from several datasets, to have sufficient power to identify
highly significant novel loci (P,5610
28). Using a large SLE
collection of 870 UK SLE cases and 5,551 UK unaffected
individuals, we firstly replicated ten moderate-risk alleles
(P,0.05) from a US–Swedish study of 3,273 SLE cases and
12,188 healthy controls. Combining our results with the
US-Swedish data identified five new loci, which crossed the
level for genome-wide significance: NCF2 (neutrophil
cytosolic factor 2), IKZF1 (Ikaros family zinc-finger 1), IRF8
(interferon regulatory factor 8), IFIH1 (interferon-induced
helicase C domain-containing protein 1), and TYK2
(tyrosine kinase 2). Each of these five genes regulates a
different aspect of the immune response and contributes
to the production of type-I and type-II interferons.
Although further studies will be required to identify the
causal alleles within these loci, the confirmation of five
new susceptibility genes for lupus makes a significant step
forward in our understanding of the genetic contribution
to SLE.
Association of Five New Genes with SLE
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previous association with IL10 (rs3024505, PUK=0.209
ORUK=1.09) (Table S5).
These analyses increased the evidence of association for a
number of additional loci that had shown borderline significance
in the original US/SWE GWAS (Table 3), including CFB,
C12ORF30, SH2B3, and IL12B. Genotyping of additional samples
will be required to determine if the association signals shown in
Table 3 represent confirmed genetic loci for SLE.
Discussion
The work presented here confirms five new susceptibility loci for
SLE at the level of genome-wide significance (P,5610
28). Each
of the associated variants lie within, or close to, the coding
sequence for genes with known roles in immune regulation: NCF2,
IKZF1, IRF8, IFIH1 and TYK2. Interestingly, each of these genes
has been implicated in interferon signalling. While the interferons
have classically been defined as anti-viral cytokines, recent studies
Table 2. Novel SNPs showing genome-wide significance (P=5 610
28) in SLE following meta-analysis of UK, US, and Swedish
cohorts.
MARKER Locus Risk allele
UK population
870 cases, 5551 controls
P value (US/SWE)
a
3273 cases, 12188 controls
Combined Analysis
Fisher’s test
P value
Freq risk allele
b OR P value OR P value
rs10911363 NCF2 T 0.27 1.23 3.02610
24 1.19 9.50610
28 2.87610
211
rs2366293 IKZF1 G 0.14 1.20 8.77610
23 1.23 2.66610
27c 2.33610
29
rs2280381 IRF8 A 0.62 1.11 0.0491 1.16 2.53610
27c 1.24610
28
rs1990760 IFIH1 T 0.61 1.11 0.0487 1.17 3.34610
27 1.63610
28
rs280519 TYK2 A 0.47 1.20 5.24610
24 1.16 7.40610
25d 3.88610
28
aFor sample numbers see reference [4] and Table S1 (US GWAS: 1310 cases and 7859 controls; US replication cohort: 1129 cases and 2991 controls; Swedish replication
cohort: 834 cases and 1388 controls).
bThe risk allele frequency was calculated in control individuals.
cUnpublished data.
dThe combined P value was calculated from imputed genotypes in the US GWAS dataset and direct genotyping in the US and SWE replication datasets.
doi:10.1371/journal.pgen.1002341.t002
Table 3. Additional SNPs showing association with SLE in the UK, US, and Swedish cohorts.
MARKER Locus Risk allele
UK population
870 cases, 5551 controls
P value (US/SWE)
a
3273 cases, 12188 controls
Combined Analysis
Fisher’s test
P value
Freq risk
allele
b OR P value OR P value
SNPs showing borderline genome-wide significance (5610
28,P,1610
27)
rs428073 TAOK3 T 0.68 1.10 0.0900 1.17 7.70610
27 6.93610
28
rs17696736 C12ORF30 G 0.43 1.21 2.05610
24 1.08 4.00610
24 8.20610
28
rs9782955 LYST C 0.75 1.05 0.450 1.18 4.60610
27 2.07610
27
rs1874791 IL12RB2 T 0.19 1.03 0.619 1.21 3.40610
27 2.10610
27
rs497273 UNQ1887 G 0.64 1.02 0.698 1.16 8.20610
27 5.72610
27
SNPs showing evidence for association in combined dataset (P.1610
27)
rs1861525 CYCS G 0.05 1.08 0.555 1.27 1.90610
26 1.05610
26
rs11951576 POLS C 0.69 1.01 0.907 1.14 4.60610
26 4.17610
26
rs641153 CFB C 0.92 1.24 0.0356 1.30 1.40610
24 4.98610
26
rs6438700 CASR C 0.82 1.01 0.947 1.18 5.50610
26 5.20610
26
rs3212227 IL12B A 0.81 1.15 0.0369 1.13 1.70610
24 6.27610
26
rs3184504 SH2B3 T 0.49 1.14 0.0156 1.11 5.57610
24 8.69610
26
rs12708716 CLEC16A A 0.65 1.10 0.0996 1.16 1.60610
24 1.59610
25
rs10516487 BANK1 C 0.68 1.12 0.0500 1.11 8.30610
24 4.15610
25
rs10156091 ICA1 T 0.11 1.04 0.604 1.16 6.50610
24 3.93610
24
rs2022013 NMNAT2 A 0.58 1.05 0.326 1.09 0.0015 4.89610
24
aFor sample numbers see reference [4] and Table S1 (US GWAS: 1310 cases and 7859 controls; US replication cohort: 1129 cases and 2991 controls; Swedish replication
cohort: 834 cases and 1388 controls).
bThe risk allele frequency was calculated in control individuals.
doi:10.1371/journal.pgen.1002341.t003
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iology of SLE [13]. While most evidence points to the role of type I
interferon in SLE [14] there is substantial data suggesting that type
II interferon (IFNc) is also involved in SLE pathogenesis [15].
NCF2 (neutrophil cytosolic factor 2) (1q25), is induced by IFNc
and specifically expressed in a number of immune-cell types,
including B-cells. Our data suggest that the NCF2 association is
independent from the previously reported signal in the neigh-
bouring locus NMNAT2, [5] because we found no evidence of
strong LD between the genotyped SNP within NMNAT2
(rs2022013) and that in NCF2 (rs10911363) (r
2=0.136). Logistic
regression in the UK replication cohort confirmed that NMNAT2
did not contribute to the association at NCF2 (P=0.777).
NCF2, as a cytosolic subunit of NADPH-oxidase, may have a
role in the increased production of the free radicals characterising
B-cell activation [16] (Figure 1) which increases auto-antibody
levels and may suggest a mechanism for the involvement of NCF2
as a susceptibility gene for SLE.
There are allele-specific significant expression differences for
rs10911363, following a recessive model of basal expression for the
risk T allele of rs10911363 in CEPH individuals but not in YRI
and ASN (CHB+JPT) HapMap cohorts (PCEPH=0.03) (Figure 2A).
There is also a significant difference in gene expression for a
variant (rs3845466) located 2 kb away from rs10911363 in intron
2o fNCF2 (Figure S2A), using lymphoblastoid cell lines (LCLs)
from umbilical cords of 75 individuals which were taken from the
GENEVAR collection (P=0.0228). The population-specific
nature of this correlation could be because of local differences in
the pattern of LD within NCF2 between the CEU, YRI and ASN
(CHB+JPT) HapMap cohorts. These population specific differ-
ences in LD may be between the genotyped SNP and an unknown
causal allele(s) responsible for an expression difference seen in
multiple ethnic backgrounds or between the genotyped marker
and an unknown causal allele(s) exhibiting population-specific
differences in gene expression itself. However, it will be necessary
to confirm these findings in primary cells and tissues, because the
EBV-transformed B cells model system may not entirely reflect the
physiological conditions in peripheral B cells. Indeed a recent
report showed that there may be systematic changes in gene
expression within EBV-transformed B cells [17]. Nevertheless,
with this caveat in mind, and taking each locus on a case-by-case
basis, the model-based approach can provide important insights
into measurement of transcript levels in ex vivo cells. For example,
the increases in transcript levels that we initially observed in EBV-
LCLs for OX40L, were also confirmed in peripheral blood B cells
[18].
IKZF1 (Ikaros family zinc-finger 1) (17p14.3) is a transcription
factor essential for dendritic cell and lymphocyte development.
The association with rs2366293 is supported by a report of a
second associated variant, rs921916 (Pcomb=2.0610
26) [4], found
860 bp away from rs2362293, which is in strong LD with
rs2366293 (r
2=20.746, D9=0.925) (Figure S2B). A third SNP,
rs4917014, located ,200 kb upstream of IKZF1, showed associ-
ation with SLE in a Chinese GWAS (PGWAS=2.93610
206), but it
was a separate signal from the European SNPs (r
2,0.0002) [9,12].
IKZF1 has a role in the production of IFNc, by blocking the
production of the Th1 master-regulator T-bet (Figure 1). The
shifted Th1/Th2 equilibrium (in favour of Th1 cells) increases the
levels of IFNc directly [19] rather than indirectly as a result of
cross-talk between the type-I and type-II IFN signalling pathways
eg) via type-I interferon mediated activation of STAT1 homodi-
mers, which are the primary means of signalling from IFNc [20]
and have recently been shown to be associated with SLE in a
Swedish cohort [21].
The transcription factor IRF8 (interferon regulatory factor 8)
(16q24.1), shows immune-cell restricted expression. rs2280381 is
found 64 kb downstream of IRF8, and is in LD with the coding
region (Figure S2C), but independent from a susceptibility allele
for multiple sclerosis (rs17445836), 1 kb away [22]. The lupus
variant influences IRF8 gene expression, since LCLs from three
HapMap cohorts, showed a significant increase in IRF8 transcript
levels in homozygotes for the risk allele (TT) compared to
homozygotes for the non-risk allele (CC) (P=0.045) (Figure 2A).
IRF8 also has a key role in regulating the differentiation of myeloid
and B-cells and in mice, IRF8 restricts myeloid cell differentiation
but promotes B-cell differentiation [23](Figure 1).
IFIH1 (interferon-induced helicase C domain-containing pro-
tein 1) (2q24.3) is an ubiquitiously expressed, cytoplasmic sensor of
dsRNA. The SLE risk allele for rs1990760 (Table 1) is identical to
that previously reported in two organ-specific autoimmune
diseases: T1D [24] and Graves’ Disease [25]. Regression analysis
using publically available genotype data from HapMap and
expression data from GEO dataset GSE12526 revealed that
individuals who were homozygous for the common risk T allele of
rs1990760 had significantly higher IFIH1 transcript levels
compared to individuals who were homozygous for the non-risk
allele (P=0.8.19610
25) (Figure S3B). Furthermore, a recent paper
showed that the presence of the risk T allele of rs1990760 was
correlated with increased levels of IFN-induced gene expression, in
lupus patients who were positive for anti-dsDNA antibodies [26].
Another report demonstrated that IFIHI was rapidly up-regulated
by type-I IFNs (Figure 1), and that IFIH1 signalled downstream
through NF-kB, to further increase IFN-a production [27].
TYK2 (tyrosine kinase 2) (19p13.2) phosphorylates the receptor
subunits of cytokine receptors, including type-I IFN receptors
which are found on all nucleated cells, leading to increased
production of type I interferon responsive genes (Figure 1). The
significant association in intron 11 TYK2 for rs280519 in our UK
cohort (P=5.24610
24) crossed the threshold for genome-wide
significance when combined with the US/Swedish cohort. The
association for rs280519 increases the genetic evidence for the
involvement of TYK2 reported in a smaller UK family-based SLE
cohort [28]. There was an earlier report, using a Swedish/Finnish
population, of association in TYK2. This Swedish/Finnish study
showed association for a missense mutation in exon 8 (rs2304256)
(Pcomb=5.60610
25, PSwe=9.60610
25) [29]. The Swedish indi-
viduals used in the earlier analysis are a subset of the Swedish
individuals analysed for this current manuscript and rs2304526 is
in moderate LD with the TYK2 SNP that we typed in this current
study - rs280519 (r
2
CEPH-HapMap=0.373). The association for
rs2304256 was replicated in a second moderate sized European
study [30], but not in the GWAS from the SLEGEN consortium
[5]. In preliminary analysis in UK cases and controls, there are
data to support the fact that rs280519 is enriched in SLE cases
(n=345) with renal disease compared to healthy controls
(n=5551) (P=0.033).
There were variants in several loci for which we have found
evidence of association (P,0.05) in our UK cohort, but which did
not reach genome-wide significance in the combined analysis. One
of these variants was rs17696736, located in intron 15 of
C12ORF30 (MDM20). This protein is a subunit of N-acetyltrans-
ferase complex B (NatB), and may promote apoptosis by reducing
cell cycle progression [31]. In the joint cohort, rs17696736 was in
LD (r
2=0.625) with a second variant on chromosome 12q24, a
missense W262R allele (rs3184504) in the lymphocyte adaptor
protein SH2B3. SH2B3 facilitates T-cell activation by mediating
the interaction between the T-cell receptor and T cell signalling
molecules [32]. Both MDM20 and SH2B3 are also associated with
Association of Five New Genes with SLE
PLoS Genetics | www.plosgenetics.org 4 October 2011 | Volume 7 | Issue 10 | e1002341Figure 1. Pathways of immuno-dysregulation by five new susceptibility genes for SLE. The figure shows the interferon-related pathways
involving NCF2, IKZF1, IRF8, IFIH1 and TYK2 and and the ways in which these pathways may contribute to lupus susceptibility. In SLE these five genes
contribute to increasing the levels of type-I and –II interferons, imbalances in Th1/Th2 related to disease severity, perturbations in B cell physiology
and production of a diverse set of auto-antibodies.
doi:10.1371/journal.pgen.1002341.g001
Association of Five New Genes with SLE
PLoS Genetics | www.plosgenetics.org 5 October 2011 | Volume 7 | Issue 10 | e1002341T1D [33], and SH2B3 is additionally associated with celiac disease
[34] and both myocardial infarction and asthma [35]. The
associated variant within IL12B, rs3212227, is located in the 39
UTR region, and the SLE risk allele is the same as previously
reported for psoriasis [36]. IL12B encodes for the larger subunit
(p40) of two cytokines, IL12 and IL23, and thereby contributes to
both Th1 [37] and Th17 [38] immune responses.
In summary, we have identified five new genes contributing to
SLE risk: NCF2, IKZF1, IRF8, IFIH1 and TYK2. Dense fine-
mapping and/or genomic re-sequencing of each locus will be
required to reveal the functional alleles for each gene with respect
to immune dysregulation in lupus. Taken together, these findings
further support an important role of interferon pathway
dysregulation in lupus pathogenesis.
Materials and Methods
Ethics statement
The ethical approval for the study was obtained from the London
Multi-Centre Research Ethics Committee (London MREC).
Details of the UK SLE samples in the study cohort
All of the 905 UK SLE cases conformed to the ACR criteria for
SLE [39] with a diagnosis of SLE being established by telephone
interview, health questionnaire and details from clinical notes.
Written consent was obtained from all participants. Genomic
DNA from the UK samples was isolated from anti-coagulated
whole blood by a standard phenol-chloroform extraction.
Genotyping methodology
Each of the 27 SNPs were genotyped on a custom Illumina
chip, using the BeadXpress platform at the Oklahoma Medical
Research Foundation (OMRF), Oklahoma. The panel of ancestry
informative markers was typed independently on an Illumina
platform at Gen-Probe, Livingstone.
Power calculations
Power calculations were performed in the UK case-control
dataset for each of the markers tested, using the algorithm
described by Purcell et al [40]. Taking into account varying minor
allele frequencies for the risk alleles and the differences in effect
size (OR), and by employing a population prevalence of 0.002 and
D9 of 1, with an type I error rates, alpha=0.05, each of the SNPs
showing novel genome-wide significance in the meta-analysis
showed a power of .48% (Table S2) to detect an association in
our cohort.
Quality control of genotyping
Markers were excluded from the analysis if they showed a
genotyping success rate of less than 95% or had a Hardy-
Weinberg P value in the B58BCC control samples of less than
P=0.001. A total of 21 cases were removed from the final analysis
due to low percentage genotyping (,95%). All samples were
filtered for cryptic relatedness and duplication using an identity by
state test in PLINK (PI_HAT score .0.1). The full list of
genotyped variants and the results of the QC analysis are shown in
(Table S3).
Correction for ancestry
A total of 35887 markers, distributed across each autosome,
were selected for ancestry correction in the UK case-control
cohort, these markers had all been typed as part of the HapMap
project and on the WTCCC2 samples. The 35887 SNPs were
chosen from a set of Illumina 317 K markers pruned for LD
Figure 2. Expression pattern in EBV-transformed lymphoblastoid cell lines. Regression analysis, as described in the materials and methods,
was performed on publically available genotype data from EBV-transformed B cells which were part of the HAPMAP collection and expression data
on the same individuals taken from the GEO database. Four populations were used: CEPH, YRI and CHB/JPT (ASN) [36]. The GEO dataset was
GSE12526 and the expression probes were: A) NCF2 (209949_at), B) IRF8 (204057_at). For each graph, the mean expression per risk (R) allele and that
for the non-risk (r) allele was plotted for each population. The alleles are listed on each bar and for each SNP, the total number of individuals for which
there was both genotype and expression data are quoted for the three populations analysed. C) Heritability estimates for each locus were taken from
the mRNA by SNP browser (http://www.sph.umich.edu/csg/liang/asthma/).
doi:10.1371/journal.pgen.1002341.g002
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2,0.25) after removing regions of known extended LD,
including the extended MHC and the region covering the inverted
repeat on chromosome 8 (pers commun. David Morris, King’s
College and Kim Taylor, UCSF). This list of AIMs is available
directly from the corresponding author, Professor Timothy Vyse.
The EIGENSTRAT PCA analysis was performed on the UK
cases and also the control samples, both from the genotyped
B58BCC and the WTCCC2 out-of-study controls. The eleven
populations from HapMap3 were used as external references.
Each SNP included in the PCA analysis showed .95%
genotyping in the each dataset. Following EIGENSTRAT
analysis, a graph was plotted of PC1 against PC2 for all the cases
and controls in the UK study cohort (Figure S1). Individuals were
only retained for association analysis if the values for their first two
principal components fell within 6 SD of the mean for the CEPH
HapMap samples. The genomic inflation factor (lambda-GC) for
each population was calculated using PLINK.
Statistical analysis
All sample genotype and phenotype data was managed by, and
analysis files generated with BC/SNPmax and BC/CLIN software
(Biocomputing Platforms Ltd, Finland).
The imputation intervals for each imputed variant, defined as
the bounds of the haplotype blocks, calculated using the Gabriel
algorithm in Haploview, (for details of the intervals see Table S2).
For SNPs which were not genotyped as part of the WTCCC2
project, we performed imputation using a method described by
Marchini et al [11] to generate the missing genotypes for case-
control association analysis. Each un-typed variant from our list of
tested SNPs, was imputed in the WTCCC2 samples, using
HAPMAP as the phased reference sequence. The LD pattern
around each un-typed variant was examined using the CEPH
cohort from HapMap. The boundaries of the haplotype blocks
were determined using the default settings for the Gabriel et al
algorithm in Haploview. For each imputed variant, these
haplotype boundaries were used to define the boundaries of the
imputation interval (Table S2). Only SNPs with greater than a
95% certainty in imputation, assessed using the quality score from
the IMPUTE2 output file, were used for subsequent analysis.
Allelic association testing, using UK SLE cases with either
genotyped control samples or imputed genotypes, was carried out
using PLINK (http://pngu.mgh.harvard.edu/,purcell/plink/).
Prior to performing the meta-analysis, the heterogeneity of odds
ratios was tested using METAL and the Cochran-Mantel-
Haenszel test (Table S4). SNPs with P value,0.001 between the
two studies were discarded. Combined analysis of P values
generated in the UK samples with those from the US/SWE
cohort in published data [4] was conducted using Fisher’s
combined P value and with a meta-analysis using the programme
METAL, which weighted the effect size, based on the inverse of
the standard error.
To determine whether there was any allele-specific effect on the
level of gene expression, we used publically available genotype
data on unrelated EBV-transformed B cells (CEU, YRI and
CHB/JPT individuals which were part of the HapMap project)
and expression data from the same individuals (GSE12526, GEO
database) [41]. For each locus, which reached genome-wide
significance by meta-analysis, we categorised the expression data
based on the SNP genotype for the respective associated variant
(homozygote risk allele, heterozygote and homozygous non-risk
allele). The significance of the correlation between genotype and
expression level was then calculated using logistic regression
analysis in SNPTEST, using gender as a covariate.
Interactions between the five SNPs reaching genome-wide
significance following meta-analysis, were assessed using the
epistatic option in PLINK. To maximize the power of this test,
we restricted our analysis to the SLE affected individuals from the
combined US/SWE/UK cohort.
Supporting Information
Figure S1 Correction for population substructure. A total of 16
UK cases and 8 out-of study controls were removed from the final
analysis because their PC1 and PC2 values were greater than 6SD
away from the mean of the PC1 and PC2 values for the CEPH
external reference individuals (20.00197.value.0.012807). The
870 SLE cases and 5551 control individuals retained for
association analysis are located within the ellipse on the graph.
(EPS)
Figure S2 Patterns of LD around the five SLE susceptibility
genes reaching genome-wide levels of significance. Patterns of
linkage disequilibrium in CEU individuals taken from HapMap,
using positions from data release 27 phase II+III Feb09, NCBI
assembly dbSNP 126: (A) 200 kb around rs10911363 (Chr 1:181,
716,380-181,916,379); (B) 155.8 kb region around rs2366293 (Chr
7:50,120,474-50,276,274); (C) 100 kb region around the gap
between IRF8 and rs2280381 (Chr 16:84500150-845600149); (D)
250 kb region around rs1990760 (Chr 2:162,700,000-162,
949,999); (E) 200 kb region around rs280519 (Chr 19: 10,
233,933-10433933).
(PDF)
Figure S3 Variants showing a trend for changes in expression in
EBV-transformed lymphoblastoid cell lines. Regression analysis, as
described in the materials and methods, was performed on
publically available genotype data from EBV-transformed B cells
which were part of the HAPMAP collection and expression data
on the same individuals taken from the GEO database. Four
populations were used: CEPH, YRI and CHB/JPT (ASN) [2].
The GEO dataset was GSE12526 and the expression probes were:
A) IKZF1 (205039_s_at), B) IFIH1 (219209_at), C) TYK2
(205546_s_at). For each graph, the mean expression per risk (R)
allele and that for the non-risk (r) allele was plotted for each
population. The alleles are listed on each bar and for each SNP,
the total number of individuals for which there was both genotype
and expression data are quoted for the three populations analysed.
D) Heritability estimates for each locus were taken from the
mRNA by SNP browser (http://www.sph.umich.edu/csg/liang/
asthma/).
(EPS)
Table S1 Composition of the study cohorts used. Each of the
seven groups of samples included in this manuscript was
independent from each other. In the UK population, direct
genotyping was carried out on UK cases
a and samples from the
British Birth Control Cohort
a (B58BCC). Genotypes from the
WTCCC2
b were used as out-of-study controls. The published data
used n the meta-analysis described in this current manuscript was
derived from US and Swedish samples. The US cohort
c consisted
of samples included in a GWAS and additional non-GWAS’d
samples used just for the replication study, as described by Gateva
et al. (2009) [4]. Full details of the Swedish (SWE)
b replication
samples are also described in Gateva et al (2009) [4].
(DOC)
Table S2 Quality control of genotype data and imputation
boundaries for WTCCC2 control samples. The position of each
variant (column ‘‘Pos’’) is given using NCBI Build 36. The number
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column marked ‘‘WTCCC2 samples.’’
(DOC)
Table S3 Power calculations.
aNovel associations in this study
(5610
28). The OR, as a measure of effect size was taken from the
case-control association study. The power was calculated accord-
ing to Purcell et al 2003 (http://bioinformatics.oxfordjournals.
org/content/19/1/149.full.pdf+html), using a disease prevalence
of 0.0002. The risk allele frequency was calculated in both cases
and controls. GRR (AB)=(ABcase/AAcase)/(ABcontrol/AAcontrol)
and GRR (AA)=(BBcase/AAcase)/(BBcontrol/AAcontrol).
(DOC)
Table S4 Results of weighted meta-analysis using METAL and
calculation of combined OR. The total number of individuals
included in the meta-analysis was: 870 UK SLE cases and 5,551
UK control samples and 3,273 SLE cases and 12,188 controls
taken from the US/SWE out-of-study cohort [1]. The risk allele
frequency quoted is that from the UK cases. The column marked
Het P-value represents the test for heterogeneity of odds ratios
between the UK and published dataset and the column marked
ORcomb represents the OR in the combined dataset, calculated
using METAL. The column marked Direction of Effect
demonstrates that the effect for each quoted allele is the same
for the UK and US/SWE datasets.
(DOC)
Table S5 Association Analysis in UK, and US-Swedish
Populations for Markers Previously Showing Genome-Wide
Significance (P,5610
28).
a For sample numbers see reference
[1] and Table S1 (US GWAS: 1,310 cases and 7,859 controls; US
replication cohort: 1,129 cases and 2,991 controls; Swedish
replication cohort: 834 cases and 1,388 controls).
b The risk allele
frequency was calculated in control individuals.
c Unpublished
data.
(DOC)
Text S1 This file contains supplementary genomic and func-
tional details about the five SLE susceptibility genes reaching
genome-wide levels of significance.
(DOC)
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